FIELD: pharmaceuticals.
SUBSTANCE: invention relates to use of compounds of formula I, or pharmaceutically acceptable salts thereof, where X, Y, Z, R1 and R2 have values given in the claim, as a pharmaceutical agent acting by inhibiting cytosolic thioredoxin reductase, and which can be used for treating cancer diseases.
(I)
EFFECT: tricyclic compounds and use thereof for treating cancer are disclosed.
10 cl, 69 ex, 3 dwg
Title | Year | Author | Number |
---|---|---|---|
PYRIDINES AND USE THEREOF IN TREATING CANCER | 2016 |
|
RU2730505C2 |
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
PYRROLE AND PYRAZOLE DAAO INHIBITORS | 2004 |
|
RU2361862C2 |
SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
VET PROTEIN DECOMPOSERS | 2017 |
|
RU2752677C2 |
SPIRO OXINDOLE MDM2 ANTAGONISTS | 2010 |
|
RU2553269C2 |
IMPROVED HONOKIOL SYNTHESIS | 2016 |
|
RU2727202C2 |
Authors
Dates
2020-11-17—Published
2016-08-05—Filed